Novo Nordisk: Competition in the starting blocks - | Caution advised?:
Roche reports success with weight loss drug CT-388; Eli Lilly and Amgen are also active in ...
deraktionaer.de/artikel/deraktionaerplus/novo-nordisk-konkurrenz-in-den-startloechern-vorsicht-angesagt-20394347.html
Story Details
| Last Updated | |
| Total Articles | 1 |
Main Topics
Similar to This
Previous
Eli Lilly shows GLP-1 weight-loss pill Foundayo can dramatically improve sleep apnea
scientificamerican.com/article/eli-lilly-shows-glp-1-weight-loss-pill-foundayo-can-dramatically-improve-sleep-apnea/
Higher sales of the Wegovy pill: Novo Nordisk raises forecast: The introduction of the Wegovy pill secures higher revenues for the Danish pharmaceutical company ...
faz.net/aktuell/wirtschaft/unternehmen/hoehere-verkaeufe-der-wegovy-pille-novo-nordisk-hebt-prognose-an-201650151.html
Lilly’s retatrutide outshines Ozempic on weight loss, blood sugar control in trial
bnnbloomberg.ca/business/company-news/2026/10/28/lillys-retatrutide-outshines-ozempic-on-weight-loss-blood-sugar-control-in-trial/
Paid articlePaywall Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top Pick
seekingalpha.com/article/4958217-novo-nordisk-vs-eli-lilly-q3-preview-id-now-buy-both-but-lilly-is-my-top-pick
STAT Oct 28
Paid articlePaywall Lilly’s triple-G drug beats Ozempic in head-to-head study: Today's biotech news includes two deaths reported in cell therapy autoimmune trial ...
statnews.com/2026/10/28/biotech-news-lillys-triple-g-drug-beats-ozempic-in-head-to-head-study/
Paid articlePaywall AbbVie is accelerating: Attack on Novo and Eli Lilly: Eli Lilly dominates the obesity market, while AbbVie is catching up with ABBV-295 in Phase 2.
deraktionaer.de/artikel/pharma-biotech/abbvie-gibt-maechtig-gas-attacke-auf-novo-und-eli-lilly-20409901.html
Paid articlePaywall In the slipstream of Eli Lilly and Novo Nordisk: AbbVie and Gubra before the next big step
deraktionaer.de/artikel/pharma-biotech/im-windschatten-von-eli-lilly-und-novo-nordisk-abbvie-und-gubra-vor-dem-naechsten-grossen-schritt-20406552.html
Paid articlePaywall Novo Nordisk vs. Eli Lilly: Surprising development in diet pills: A surprising development is emerging in the new diet pill market. In the battle of the giants ...
deraktionaer.de/artikel/deraktionaerplus/novo-nordisk-vs-eli-lilly-ueberraschende-entwicklung-bei-den-abnehmpillen--20404781.html
Billion-Dollar Obesity Jackpot: Amgen & Roche Declare War on Novo & Lilly!: AI Bubble? Wedbush Analyst Daniel Ives emphatically denies it! He sees a $3 trillion ...
wallstreet-online.de/nachricht/20216811-rennen-milliarden-jackpot-adipositas-amgen-roche-novo-lilly-kampf-an
Novo Nordisk cuts 9,000 jobs in the competition for weight-loss injections: The pharmaceutical company, which rose to become Europe's most valuable company ...
faz.net/aktuell/wirtschaft/unternehmen/novo-nordisk-streicht-9000-stellen-im-wettbewerb-um-abnehmspritzen-accg-110678848.html
Trump's drug price ultimatum sets pharma firms scrambling: A fresh ultimatum demanding "binding commitments" to lower U.S. drug prices sent pharma firms ...
cnbc.com/2025/08/01/trumps-drug-price-ultimatum-sets-pharma-firms-scrambling.html
Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup
qz.com/wegovy-ozempic-weight-loss-drugs-amgen-maritide-1851768247
Paid articlePaywall Investments: Three alternatives to Eli Lilly and Novo Nordisk: New providers are entering the booming market for weight-loss products. Analysts see a lot of ...
handelsblatt.com/finanzen/maerkte/aktien/geldanlage-drei-alternativen-zu-eli-lilly-und-novo-nordisk/100088147.html
New Obesity Drug MariTide Helps Patients Lose Up to 20% of Weight, Early Data Shows
nytimes.com/2024/11/26/health/weight-loss-drug-maritide-amgen.html
help.medscape.com Oct 11 24
Because screening [for MASLD/MASH] isn’t widespread, patients often aren’t diagnosed until they experience complications of cirrhosis ... Show more
📌MASH Clinical Fact: Don't forget to screen your at-risk patients for metabolic dysfunction-associated steatohepatitis. The 5 most common risk factors to ... Show more
Clinical Advances in MASH: A Guide to Managing Metabolic-Dysfunction Associated Steatohepatitis
medscape.org/sites/advances/mash-advances
Paid articlePaywall Hot week: Amgen, Novo Nordisk and Eli Lilly before figures - | Megatrend obesity in focus
deraktionaer.de/artikel/pharma-biotech/heisse-woche-amgen-novo-nordisk-und-eli-lilly-vor-zahlen-megatrend-adipositas-im-blick-20363571.html
Paid articlePaywall Amgen Could Become A Real Contender In The Obesity Market: Amgen's shares surge on positive phase 2 trial results for obesity candidate MariTide ...
seekingalpha.com/article/4689415-amgen-could-become-real-contender-obesity-market
Key FactsAmgen stock price soars after unveiling new monthly weight loss drug
May 3, 2024 · Reading time: ~30 sec.
Summary created with AI assistance · Source: markets.businessinsider.com
Summary created with AI assistance · Source: markets.businessinsider.com
- An experimental weight loss drug from Amgen led to a 16% rally in the stock price.
- Amgen reported first-quarter earnings that exceeded analyst estimates. It also adjusted its 2024 revenue and profit forecasts slightly higher, with investors more interested in an update on the pipeline development of the GLP-1 weight loss drug called Mari Tide.
- Amgen plans to release top-line data from Mari Tide's phase 2 trial by late 2024. Goldman Sachs estimates that if approved, Amgen's Mari Tide could have peak sales of $5 billion or about 5% of the $100 billion obesity market.
- A monthly or less frequent injection would not only enhance convenience for patients but also help alleviate the supply constraints of GLP-1 weight loss drugs.
Next